Spark’s Hemophilia Gene Therapy Remains Effective Despite Immune Reactions – TheStreet.com
TheStreet.com |
Spark's Hemophilia Gene Therapy Remains Effective Despite Immune Reactions
TheStreet.com Two patients with hemophilia B experienced adverse autoimmune reactions to a gene therapy from Spark Therapeutics (ONCE) , necessitating treatment with steroids and resulting in the production of lower levels of the blood-clotting protein factor IX … After gene therapy, hemophilia B patients maintain near-normal levels of clotting factor Gene therapy stops bleeding for hemophilia patients |
